RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.
A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
- Chemical Identification
- Environmental Hazards
- First Aid/Medical Treatment
- Handling/Storage/Shipping/Waste Management
- Personal Protection
- Physical Hazards/Corrective Response Actions
- Physical/Chemical Properties
- Report Abstracts and Studies
- Reproductive Risk
- Toxicology/Health Hazards/Exposure
|Example of Acute Exposure data from MEDITEXT.|
RightAnswer Proprietary Data Sources:
Other Government Links Searched via RegsKnowledge:
State Environmental Regulations
Example Content from MEDITEXT for Bortezomib:
Please note: this is an extract of information from a larger document. Full document and details are available by subscription.
ACUTE EXPOSURE INFORMATION
- WITH THERAPEUTIC USE
- Adverse effects reported with bortezomib therapy have included gastrointestinal effects (nausea (57%), vomiting (35%), diarrhea (57%), decreased appetite (34%), abdominal pain (16%), and constipation (42%)), fever (35%), thrombocytopenia (35%), neutropenia (19%), anemia (26%), asthenia (fatigue, malaise, weakness) (61%), peripheral neuropathy (36%) and hypotension (13%). In postmarketing experience, complete atrioventricular block, cardiac tamponade, ischemic colitis, encephalopathy, dysautonomia, bilateral deafness, DIC, hepatitis, acute pancreatitis, and toxic epidermal necrolysis have occurred.
- Other adverse effects included rash, hyponatremia, hypokalemia, paralytic ileus, hyperbilirubinemia, increases in liver enzymes, hepatitis, bone pain, myalgia, rhabdomyolysis, leukoencephalopathy, headache, dizziness, paresthesia and dysesthesia, psychiatric disorders, cough, dyspnea, nasopharyngitis, fever, rigor, and tumor lysis syndrome.
- WITH POISONING/EXPOSURE
- OVERDOSE: Limited data. Twice the recommended dose has resulted in an acute onset of hypotension and thrombocytopenia resulting in fatal outcomes.
© 2011-2021 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.